Vitama NatureP.S.A.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2022-06-15
Share capital
5,000.00 PLN
Registered address
ul. Sokołowska 9/U19, 01-142 Warszawa, Poland
Electronic delivery address
AE:PL-10424-46374-GBGVU-25

Financials

Revenue history (in k)

Filing timeliness

No financial statement for 2024 – the filing deadline has passed. 2 of 2 financial statements were filed late (the longest delay 446 days for 2022).

  • 2024not filed
  • 202303/10/2024
  • 202203/10/2024
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2023.

Industry · Manufacture of pharmaceutical preparations142 / 258
Top 55%
Division · Manufacture of basic pharmaceutical products and pharmaceutical preparations165 / 330
Top 50%
Sector · Manufacturing17,361 / 33,759
Top 51%
Voivodeship · Mazowieckie42,576 / 142,058
Top 30%
Country · Poland156,010 / 495,976
Top 31%

Results vs industry

Revenue
This companyUSD 589.73kMedianUSD 919.05kAverageUSD 25.83m
Net profit
This companyUSD -3.55kMedianUSD 14.92kAverageUSD 2.77m
Operating costs
This companyUSD 590.44kMedianUSD 873.06kAverageUSD 21.42m
Assets
This companyUSD 211.03kMedianUSD 897.46kAverageUSD 31.52m

Industry

Trademarks

Vitama Nature holds 14 active trademarks registered with the Polish Patent Office. 4 marks have expired or were not registered. The first mark was filed in 2013.

MarkNumberClassesStatusProtected until
BUTRYSALZ.5389465Protected Jan 21, 2032
XYLOPRONAL(word)Z.5139305Protected May 25, 2030
SOLICLAR(word)Z.5139205Protected May 25, 2030
ASPICONT(word)Z.5139105Protected May 25, 2030
STOPELOP(word)Z.5139065Protected May 25, 2030
MarkProtected until
BUTRYSALJan 21, 2032
XYLOPRONAL(word)May 25, 2030
SOLICLAR(word)May 25, 2030
ASPICONT(word)May 25, 2030
STOPELOP(word)May 25, 2030

Authorized Representatives

Marek Kazimierz Lubicz-Nowickiage 75 – President of the Management Board

Manner of representation

Each member of the management board is authorized to make declarations on behalf of the company independently.

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2022-08-01.

  • mBank
    mBank
    11 1140 1010 0000 4728 3500 1002
  • mBank
    mBank
    38 1140 1010 0000 4728 3500 1001
  • mBank
    mBank
    54 1140 1010 0000 4728 3500 1004

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Anpharm Przedsiębiorstwo FarmaceutyczneS.A.
Tarchomińskie Zakłady Farmaceutyczne PolfaS.A.
VercoS.A.
MedicofarmaS.A.
VitamaS.A.
Munar PharmaS.A.
Sanford Biotechsp. z o.o.
Cefeasp. z o.o.
Auxilius PharmaS.A.
Stg25Branch (foreign co.)

FAQ

Last updated: 2026-04-02